alecensa
roche registration gmbh - alectinib-hydrokloridia - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - alecensa monoterapiana on tarkoitettu ensilinjan hoito aikuispotilailla, anaplastinen lymfooma kinaasi (alk)-positiivinen pitkälle edennyt ei-pienisoluinen keuhkosyöpä (nsclc). alecensa monoterapiana on tarkoitettu aikuisille potilaille, joilla on alk‑positiivinen, edennyt ei-pienisoluinen keuhkosyöpä aiemmin käsitelty crizotinib.
lorviqua
pfizer europe ma eeig - lorlatinib - karsinooma, ei-pienisoluinen keuhko - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
flecainide orion 100 mg depotkapseli, kova
orion corporation - flecainide acetate - depotkapseli, kova - 100 mg - flekainidi
flecainide orion 200 mg depotkapseli, kova
orion corporation - flecainide acetate - depotkapseli, kova - 200 mg - flekainidi
flecainid actavis 100 mg tabletti
actavis group ptc ehf - flecainidi acetas - tabletti - 100 mg - flekainidi
flecainide stada 100 mg tabletti
stada arzneimittel ag - flecainidi acetas - tabletti - 100 mg - flekainidi
flecainid alternova 100 mg tabletti
alternova oy ab - flecainidi acetas - tabletti - 100 mg - flekainidi
tambocor 10 mg/ml injektioneste, liuos
viatris oy - flecainide acetate - injektioneste, liuos - 10 mg/ml - flekainidi
tambocor retard 100 mg depotkapseli, kova
viatris oy - flecainide acetate - depotkapseli, kova - 100 mg - flekainidi
tambocor retard 200 mg depotkapseli, kova
viatris oy - flecainide acetate - depotkapseli, kova - 200 mg - flekainidi